Eurofins Scientific (ENXTPA:ERF) Stock Could Be 47% Cheap Based On Cash Flow
Eurofins Scientific stock has logged a mixed record for shareholders, with a rise over the past year but a decline over five years. A fresh intrinsic value estimate points to a large potential discount to its current share price. The question for you is whether that discount reflects mispricing or simply the market’s view of the risks around the company’s future cash flows.
- Eurofins Scientific shares are down 38.3% over five years, which suggests long term holders have faced a material capital loss despite more recent gains.
- The intrinsic value estimate, based on a Discounted Cash Flow and currently indicating the stock trades about 47.4% below that estimate, can be supported or undermined by how reliably Eurofins converts its testing and laboratory revenues into durable free cash flow. Any pressure on margins or heavier investment needs may limit how much of that theoretical value is realised.
- On a broader set of valuation checks, Eurofins Scientific screens as cheap, with the company looking undervalued in 5 of 6 tests, even though market multiples on their own appear roughly in line with peers.
For investors, the debate is whether Eurofins Scientific’s share price already reflects the long term risks to its cash flows or if the current discount to intrinsic value leaves meaningful upside if the business delivers as expected.
Spot opportunities beyond Eurofins Scientific by scanning a curated list of resilient, value focused stocks in the 300 resilient stocks with low risk scores.Is Eurofins Scientific a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach values Eurofins Scientific based on the cash it is expected to generate for shareholders. The model starts from latest twelve month free cash flow of about €834 million and assumes that cash generation grows over time rather than shrinking, consistent with the supplied projections.
On those assumptions, the DCF framework points to an intrinsic value of about €135.97 per share. Compared with the current market price, this implies the stock trades at roughly a 47.4% discount, which suggests investors today are pricing in significantly more risk to Eurofins Scientific’s future cash flows than the model does.
Overall, the Discounted Cash Flow outcome indicates Eurofins Scientific stock currently appears undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Eurofins Scientific is undervalued by 47.4%. Track this in your watchlist or portfolio, or discover 257 more high quality undervalued stocks.
Does Eurofins Scientific Look Fairly Valued on Earnings?
The P/E ratio suits Eurofins Scientific because earnings are a central focus for many investors in the Life Sciences sector. Eurofins currently trades on a P/E of about 26.4x, compared with an industry average of around 37.6x and a peer group average near 32.2x. That places the stock below broad sector pricing on earnings, even though it remains well within the usual range for established listed laboratory businesses.
A tailored fair P/E for Eurofins Scientific, which factors in the company’s size, sector, profitability profile and risk, is estimated at about 28.2x. The current 26.4x level sits a little below that reference point, so the market is applying only a modest discount to what this framework suggests could be typical for the stock.
On balance, Eurofins Scientific appears roughly fairly valued on its current P/E multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Eurofins Scientific Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Eurofins Scientific pick up where the valuation puzzle leaves off and spell out which paths for growth, margins and earnings would make the stock look materially higher or lower than today’s price. Each one ties its number to a clear view of how Eurofins Scientific's growth, profitability and risks could evolve, which you can revisit as new information and results emerge.
Community views on Eurofins Scientific could hardly be further apart, with one camp focusing on long term investments in the business and the other on pressure from disruption and acquisitions.
Bull case: roughly fairly valued
"The company's significant investments in automation, digitalization, and its hub-and-spoke laboratory infrastructure are expected to materially improve operating efficiency and scalability by 2027..."
Read the full Bull Case to see why Eurofins Scientific could be undervalued
Bear case: 23% overvalued
"The accelerating pace of automation, AI-driven data analysis, and decentralized/point-of-care testing threatens to erode Eurofins' growth potential in traditional laboratory services..."
Read the full Bear Case to see why Eurofins Scientific could be overvalued
Do you think there's more to the story for Eurofins Scientific? Head over to our Community to see what others are saying!
The Bottom Line
Eurofins Scientific screens as undervalued on the Discounted Cash Flow (DCF) intrinsic value estimate, yet its current P/E suggests the market prices the stock at about the right level on earnings. That mix points to a potential gap between what long term cash flows could be worth and what investors are currently willing to pay based on near term growth and sentiment. The crux for Eurofins Scientific now is whether it can turn its laboratory network and investments into resilient free cash flow without needing heavier reinvestment than expected.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com